## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

TA T	c		
Name	ot	entity	7

#### ELK PETROLEUM LTD

ABN

38 112 566 499

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- 1. Fully paid Ordinary shares (ELK)
- 2. Unlisted Performance Rights, Conversion Price VWAP over 20 days prior to 30 June 2017 (ELKAK)
- 3. Unlisted Performance Rights CEO (ELKAK)
- Unlisted Retention Rights, Conversion Price VWAP over 20 days prior to and including 30 June 2017 (ELKAI)
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. 656,908 Fully paid Ordinary shares (ELK)
- 2. (2,833,119) Performance Rights, Conversion Price – VWAP over 20 days prior to 30 June 2017 (ELKAK)
- 3. (2,000,000) Performance Rights CEO (ELKAK)
- (719,680) Retention Rights, Conversion Price – VWAP over 20 days prior to and including 30 June 2017 (ELKAI)

3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	<ol> <li>Fully paid Ordinary shares (ELK)</li> <li>Performance Rights, Conversion Price – VWAP over 20 days prior to 30 June 2017 (ELKAK)</li> <li>Performance Rights CEO (ELKAK)</li> <li>Retention Rights, Conversion Price – VWAP over 20 days prior to and including 30 June 2017 (ELKAI)</li> </ol>
4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	1. Yes 2. N/A 3. N/A 4. N/A
5	Issue price or consideration	<ol> <li>Retention right conversion VWAP calculated price of \$0.063722</li> <li>N/A</li> <li>N/A</li> <li>N/A</li> </ol>
_	Division of the issue	1. 2014 Bararian dala amanda
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ol> <li>2014 Retention right conversion</li> <li>2014 Performance right lapsing</li> <li>Performance right CEO lapsing</li> <li>2014 Retention right vesting</li> </ol>
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution	28 November 2016
	under rule 7.1A was passed	

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	1. 656,908 Fully paid Ordinary shares (ELK): 21 November 2014 (LR 7.2 Exception 9; LR 10.12 Exception 4) 2. N/A 3. N/A 4. N/A
6f	Number of *securities issued under an exception in rule 7.2	<ol> <li>656,908 Fully paid Ordinary shares (ELK): 21         November 2014 (LR 7.2 Exception 9; LR 10.12 Exception 4)     </li> <li>N/A</li> <li>N/A</li> <li>N/A</li> </ol>
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to annexure 1
7	<sup>+</sup> Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	1. 30 June 2017 2. 30 June 2017 3. 30 June 2017 4. 30 June 2017

Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	+Class
854,046,208	Ordinary shares (ASX:ELK)
+	
656,908	
854,703,117	
22,675,000	Listed Options, Exercise Price \$0.25, Expiry date 22/07/2017 (ASX: ELKO)

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
719,680	Retention Rights
-	Conversion Price –
(719,680)	VWAP over 20 days prior to and including 30
0	June 2017
183,595	Retention Rights Conversion Price – VWAP over 20 days prior to and including 30 June 2018
475,000	Retention Rights Conversion Price – VWAP over 20 days prior to and including 30 June 2019
658,595	Total Class - ELKAI

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4,000,000 - (2,000,000) - 2,000,000	Performance Rights CEO
2,833,119 - (2,833,119) 0	Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017
1,870,000	Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018
4,260,000	Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2019
9 120 000	Total Class FI KAK
<b>8,130,000</b> 18,333,333	Options (Unlisted) over unissued ordinary shares (ELKAM)
18,333,333	Total Class - ELKAM
Agreement to issue up to: 183,796,638 shares	Convertible Loan Facility (ELKAN)
183,796,638	Total Class - ELKAN

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) N/A

#### Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
	_	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	
Dart	3 - Quotation of securitie	e
	ed only complete this section if you are appl	
34	Type of *securities (tick one)	
(a)	*Securities described in Part 1	
(b)		of the escrowed period, partly paid securities that become fully paid, employeends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

Additional securities forming a new class of securities

11ск то docume	indicate you are providing the information or nts
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over
37	A copy of any trust deed for the additional *securities
Entiti	es that have ticked box 34(b)
38	Number of *securities for which *quotation is sought
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?
	If the additional *securities do not rank equally, please state:  1. the date from which they do  2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
41	Reason for request for quotation now
	Example: In the case of restricted securities, end of restriction period
	(if issued upon conversion of another *security, clearly identify that other *security)

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	+Class

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Joint Company secretary)	Date: 5 July 2017
Print name:	David Franks	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figures capacity is calculated	ıre from which the placement
Insert number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	672,309,014
Add the following:	
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	148,474,840
Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval	33,919,262
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	0
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	0
"A"	854,703,116

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	128,205,467	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	18,890,649	
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	18,890,649	
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	128,205,467	
Note: number must be same as shown in Step 2		
Subtract "C"	18,890,649	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	109,314,818	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
854,703,116		
Step 2: Calculate 10% of "A"		
0.10		
Note: this value cannot be changed		
85,470,311		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
0		
0		

04/03/2013 Appendix 3B Page 13

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	85,470,311	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	85,470,311	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.